Characteristics Associated with Acute-Phase Response following First Zoledronic Acid Infusion in Brazilian Population with Osteoporosis
Table 2
Demographic and clinical characteristics of 400 patients according to the presence or absence of zoledronic acid infusion acute-phase response.
Characteristics
Acute-phase response
value
Absent
Present
Patients, n (%)
302 (75.5)
98 (24.5)
Female, n (%)
241 (79.8)
77 (78.6)
0.79
Age (years); mean ± SD
71.4 ± 10.9
67.2 ± 11.6
0.001
Age categories, n (%)
≤66 years
92 (30.5%)
47 (48.0%)
0.001
67–75 years
100 (33.1%)
32 (32.7%)
>75 years
110 (36.4%)
19 (19.4%)
Oral bisphosphonate-prior use, n (%)
151 (50.0%)
33 (33.7%)
0.005
BMI (kg/m2), mean ± SD
25.88 ± 4.88
25.87 ± 4.68
0.99
Diabetes, n (%)
47 (15.6%)
12 (12.2%)
0.42
Smoking, n (%)
Never
177 (58.6%)
50 (51.0%)
0.11
Former
98 (32.5%)
43 (43.9%)
Active
25 (8.3%)
5 (5.1%)
25-Hydroxyvitamin D, median [25–75th percentile]
Baseline (ng/mL)
32.0 [25.0, 39.0]
32.0 [26.0, 37.0]
0.91
After infusion (ng/mL)
31.0 [25.0, 39.0]
30.0 [23.0, 36.0]
0.27
Group low-low × normal-normal (n)
56 × 44
20 × 7
0.14
Total calcium (mg/dL), median [25–75th percentile]
9.2 [8.9, 9.6]
9.2 [8.9, 9.7]
0.22
PTH, median [25–75th percentile]
49.0 [37.5, 62.0]
52.0 [43.0, 64.0]
0.18
eGFR level (mL/minute), mean ± SD
59 ± 16
62 ± 17
0.17
CTX, median [25–75th percentile]
Baseline, ng/mL
0.430 [0.249, 0.700]
0.535 [0.375, 0.679]
0.026
After infusion, ng/mL
0.182 [0.125, 0.267]
0.170 [0.122, 0.274]
0.59
ΔCTX median [25–75th percentile]
−53.7 [−72.1, −23.4]
−69.3 [−76.2, −49.7]
0.002
BMI, body mass index; PTH, parathyroid hormone; eGFR, estimated glomerular filtration rate, measured by CKD-EPI creatinine equation; CTX, carboxy-terminal crosslinked telopeptide of type 1 collagen; ΔCTX: delta carboxy-terminal crosslinked telopeptide of type 1 collagen.
